Avidity Biosciences, Inc. completed a merger on February 27, 2026, becoming a wholly owned subsidiary of Parent, with all common stock converted to Merger Consideration and trading suspended on Nasdaq effective March 2, 2026. All directors and executive officers resigned or were removed, new leadership from Merger Sub was appointed, and governing documents were amended and restated.
Key takeaways
Merger closed February 27, 2026; Company became wholly owned subsidiary of Parent
Company Common Stock delisted from Nasdaq; trading suspended March 2, 2026
All prior directors resigned effective Effective Time: Carsten Boess, Sarah Boyce, Troy Wilson Ph.D. J.D., Arthur A. Levin Ph.D., Simona Skerjanec, Tamar Thompson, Noreen Henig M.D., Edward M. Kaye M.D., Jean Kim
New directors: Jaime Huertas, Eduard Marti
All executive officers removed; new officers: John McKenna (President), Eduard Marti (Treasurer), Jamie Huertas (Secretary)
Certificate of incorporation and bylaws amended and restated per Merger Agreement